ViiV HEALTHCARE RANKED #1 BY PATIENT GROUPS FOR 13TH SUCCESSIVE YEAR IN PATIENTVIEW’S ‘CORPORATE REPUTATION OF PHARMA – FROM THE PATIENT PERSPECTIVE 2025 - 2026’ SURVEY
Media Contacts
For US-specific media inquiries, email:
melinda.x.stubbee@viivhealthcare.com
OR call +1 919 491 0831
For our corporate press office:
call +44 7557 290 420
London, 30 April 2026 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi a shareholder, today announced it has been ranked as the #1 pharmaceutical company by patient groups for the 13th consecutive year in PatientView’s Corporate Reputation of Pharma survey.
PatientView is an independent research group that collects and analyses the perspectives of patient groups worldwide. Each year it publishes the results of a survey ranking the reputation of global pharmaceutical companies as voted for by patient groups. ViiV Healthcare ranked #1 across all patient-defined reputation indicators including: patient centricity, information and safety; engagement in R&D; benefit of products; access to medicines; transparency in pricing and clinical data; and patient group relations.
Jean Van Wyk, Chief Medical Officer at ViiV Healthcare, said: “Being ranked #1 by patient groups for the 13th consecutive year is a source of immense pride for ViiV Healthcare and we deeply value this recognition from our community partners and patient groups. Their insight, challenge and collaboration shape everything we do, from discovering and developing new medicines to designing inclusive clinical trials and addressing stigma and structural barriers to HIV services. As the only company 100% dedicated to treating, preventing and curing HIV, we remain committed to community partnerships that drive better outcomes and progress towards our shared goal of ending the HIV epidemic.”
This recognition reinforces ViiV Healthcare’s commitment to building long-term relationships with the communities it serves, putting people at the centre of the HIV response and developing the next generation of HIV medicines that people tell us they want and need.
Angelina Namiba, Founder, 4M Network of Mentor Mothers, said: “ViiV Healthcare has been by our side since our beginning, and over the last decade our collaboration has truly exemplified how meaningful engagement and trusted partnerships between industry and community-based HIV organisations can drive innovation and lead to better outcomes. Our success lies in ‘active partnership’ – ViiV don’t just fund us, they work with us to ensure our voices and lived experiences shape lasting progress, both within and beyond healthcare.”
Dr Keith Green, Executive Director, Chicago Black Gay Men’s Caucus, said: “What sets ViiV Healthcare apart as a partner is its willingness to get to the heart of the work – removing layers and barriers so we can take action and create space for building community.”
With the number of people living with HIV rising each year, meaningful collaboration between those impacted by HIV and the pharmaceutical industry has never been more vital. ViiV Healthcare remains committed to powerful partnerships that put the community at the heart of everything it does to accelerate progress against ending the HIV epidemic for everyone, everywhere.
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 with GSK (LSE: GSK) and Shionogi as current shareholders. The company is dedicated to delivering advances in treatment and care for people living with HIV and for people who could benefit from HIV prevention. ViiV Healthcare’s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV. Find out more at viivhealthcare.com
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
About PatientView
PatientView is a research company formed in 2000 in response to the growing importance of patient groups and examines, and publicises, the importance of patient groups worldwide. PatientView believes that the patient voice is essential in all aspects of healthcare and works with patient groups from almost every country, and from most therapeutic areas. PatientView is an entirely independent body, and conducts its studies independently. It funds the annual ‘Corporate Reputation of Pharma’ study solely by itself, from the sales of the survey results to governments, regulators, payors, and the pharmaceutical and medical device industries. For more information, please visit patient-view.com
About the ‘Corporate Reputation of Pharma’ survey
PatientView annually surveys patient groups across a breadth of disease areas and geographies. The survey results provide patient perspectives on how the pharma industry has performed over the last 12 months. Inside the report, are evidence-based insights and rankings – both for individual pharma companies, and for the wider industry’s performance. Pharma companies can also find actionable steps and recommendations to improve future rankings. Patient groups responding to the 2025/2026 ‘Corporate Reputation’ survey are actively engaging in discussions (and partnering) with stakeholders across the healthcare sector. The insights gained from the ‘Corporate Reputation’ research helps pharma companies to better address, and align with, patient needs and perspectives.
| ViiV Healthcare enquiries: | |||
| Media: | Kate Senter | +44 (0) 77 9670 7446 | (London) |
| GSK enquiries: | |||
| Media: | Simon Steel | +44 (0) 20 8047 5502 | (London) |
| Sarah Clements | +44 (0) 20 8047 5502 |
(London) | |
| Kathleen Quinn | +1 202 603 5003 | (Washington DC) | |
| Alison Hunt | +1 540 742 3391 | (Washington DC) | |
| Investor Relations: | Constantin Fest | +44 (0) 7831 826525 | (London) |
| James Dodwell | +44 (0) 20 8047 2406 | (London) | |
| Mick Readey | +44 (0) 7990 339653 | (London) | |
| Sam Piper | +44 (0) 7824 525779 | (London) | |
| Jeff McLaughlin | +1 215 751 7002 | (Philadelphia) | |
| Frannie DeFranco | +1 215 751 3126 | (Philadelphia) | |
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2025, and GSK’s Q1 Results for 2026.
Registered in England & Wales:
GSK plc ViiV Healthcare Limited
No. 3888792 No. 06876960
Registered Office:
79 New Oxford Street ViiV Healthcare Limited
London GSK Medicines Research Centre
WC1A 1DG Gunnels Wood Road, Stevenage
United Kingdom
SG1 2NY
